Simian-tropic HIV as a model to study drug resistance against integrase inhibitors

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 4, 2015, Pages 1942-1949

  Wares, Melissa ^a,b   Hassounah, Said ^a,c   Mesplède, Thibault ^a   Sandstrom, Paul A ^d   Wainberg, Mark A ^a,b,c  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d PUBLIC HEALTH AGENCY OF CANADA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DOLUTEGRAVIR; ELVITEGRAVIR; RALTEGRAVIR; FUSED HETEROCYCLIC RINGS; INTEGRASE INHIBITOR; QUINOLONE DERIVATIVE;

ANIMAL CELL; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RHESUS MONKEY; SIMIAN IMMUNODEFICIENCY VIRUS; SITE DIRECTED MUTAGENESIS; T LYMPHOCYTE; VIRAL TROPISM; VIROGENESIS; VIRUS CONCENTRATION; VIRUS INFECTIVITY; VIRUS MUTANT; VIRUS RECOMBINANT; VIRUS REPLICATION; ANIMAL; BIOLOGICAL MODEL; CELL LINE; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST;

ANIMALS; CELL LINE; DRUG RESISTANCE, VIRAL; HETEROCYCLIC COMPOUNDS, 3-RING; HIV INTEGRASE INHIBITORS; HUMANS; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; MUTAGENESIS, SITE-DIRECTED; QUINOLONES; RALTEGRAVIR POTASSIUM; SIMIAN IMMUNODEFICIENCY VIRUS; VIRUS REPLICATION;

EID: 84928902238     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.04829-14     Document Type: Article

References (39)

1. Van Rompay KK. 2010. Evaluation of antiretrovirals in animal models of HIV infection. Antiviral Res 85:159-175. http://dx.doi.org/10.1016/j.antiviral.2009.07.008.
2. Na L, Tang YD, Liu JD, Yu CQ, Sun LK, Lin YZ, Wang XF, Wang X, Zhou JH. 2014. TRIMe7-CypA, an alternative splicing isoform of TRIMCyp in rhesus macaque, negatively modulates TRIM5alpha activity. Biochem Biophys Res Commun 446:470-474. http://dx.doi.org/10.1016/j.bbrc.2014.02.132.
3. Borda JT, Alvarez X, Kondova I, Aye P, Simon MA, Desrosiers RC, Lackner AA. 2004. Cell tropism of simian immunodeficiency virus in culture is not predictive of in vivo tropism or pathogenesis. Am J Pathol 165:2111-2122. http://dx.doi.org/10.1016/S0002-9440(10)63261-0.
4. Lohman BL, McChesney MB, Miller CJ, McGowan E, Joye SM, Van Rompay KK, Reay E, Antipa L, Pedersen NC, Marthas ML. 1994. A partially attenuated simian immunodeficiency virus induces host immunity that correlates with resistance to pathogenic virus challenge. J Virol 68:7021-7029.
5. Hatziioannou T, Princiotta M, Piatak M, Jr, Yuan F, Zhang F, Lifson JD, Bieniasz PD. 2006. Generation of simian-tropic HIV-1 by restriction factor evasion. Science 314:95. http://dx.doi.org/10.1126/science.1130994.
6. Kamada K, Igarashi T, Martin MA, Khamsri B, Hatcho K, Yamashita T, Fujita M, Uchiyama T, Adachi A. 2006. Generation of HIV-1 derivatives that productively infect macaque monkey lymphoid cells. Proc Natl Acad Sci U S A 103:16959-16964. http://dx.doi.org/10.1073/pnas.0608289103.
7. Mesplède T, Quashie PK, Zanichelli V, Wainberg MA. 2014. Integrase strand transfer inhibitors in the management of HIV-positive individuals. Ann Med 46:123-129. http://dx.doi.org/10.3109/07853890.2014.883169.
8. Mouscadet JF, Delelis O, Marcelin AG, Tchertanov L. 2010. Resistance to HIV-1 integrase inhibitors: a structural perspective. Drug Resist Updat 13:139-150. http://dx.doi.org/10.1016/j.drup.2010.05.001.
9. Huang W, Frantzell A, Fransen S, Petropoulos CJ. 2013. Multiple genetic pathways involving amino acid position 143 of HIV-1 integrase are preferentially associated with specific secondary amino acid substitutions and confer resistance to raltegravir and cross-resistance to elvitegravir. Antimicrob Agents Chemother 57:4105-4113. http://dx.doi.org/10.1128/AAC.00204-13.
10. Quashie PK, Mesplède T, Wainberg MA. 2013. Evolution of HIV integrase resistance mutations. Curr Opin Infect Dis 26:43-49.
11. Wainberg MA, Mesplède T, Raffi F. 2013. What if HIV were unable to develop resistance against a new therapeutic agent? BMC Med 11:249. http://dx.doi.org/10.1186/1741-7015-11-249.
12. Walmsley SL, Antela A, Clumeck N, Duiculescu D, Eberhard A, Gutierrez F, Hocqueloux L, Maggiolo F, Sandkovsky U, Granier C, Pappa K, Wynne B, Min S, Nichols G. 2013. Dolutegravir plus abacavirlamivudine for the treatment of HIV-1 infection. N Engl J Med 369:1807-1818. http://dx.doi.org/10.1056/NEJMoa1215541.
13. Raffi F, Rachlis A, Stellbrink HJ, Hardy WD, Torti C, Orkin C, Bloch M, Podzamczer D, Pokrovsky V, Pulido F, Almond S, Margolis D, Brennan C, Min S. 2013. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, noninferiority SPRING-2 study. Lancet 381: 735-743. http://dx.doi.org/10.1016/S0140-6736(12)61853-4.
14. Raffi F, Jaeger H, Quiros-Roldan E, Albrecht H, Belonosova E, Gatell JM, Baril JG, Domingo P, Brennan C, Almond S, Min S. 2013. Oncedaily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, noninferiority trial. Lancet Infect Dis 13:927-935. http://dx.doi.org/10.1016/S1473-3099(13)70257-3.
15. Bar-Magen T, Sloan RD, Donahue DA, Kuhl BD, Zabeida A, Xu H, Oliveira M, Hazuda DJ, Wainberg MA. 2010. Identification of novel mutations responsible for resistance to MK-2048, a second-generation HIV-1 integrase inhibitor. J Virol 84:9210-9216. http://dx.doi.org/10.1128/JVI.01164-10.
16. Quashie PK, Mesplède T, Han YS, Oliveira M, Singhroy DN, Fujiwara T, Underwood MR, Wainberg MA. 2012. Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir. J Virol 86:2696-2705. http://dx.doi.org/10.1128/JVI.06591-11.
17. Malet I, Fourati S, Charpentier C, Morand-Joubert L, Armenia D, Wirden M, Sayon S, Van Houtte M, Ceccherini-Silberstein F, Brun-Vezinet F, Perno CF, Descamps D, Capt A, Calvez V, Marcelin AG. 2011. The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02-AG HIV-1 subtype. J Antimicrob Chemother 66:2827-2830. http://dx.doi.org/10.1093/jac/dkr389.
18. Kobayashi M, Yoshinaga T, Seki T, Wakasa-Morimoto C, Brown KW, Ferris R, Foster SA, Hazen RJ, Miki S, Suyama-Kagitani A, Kawauchi-Miki S, Taishi T, Kawasuji T, Johns BA, Underwood MR, Garvey EP, Sato A, Fujiwara T. 2011. In vitro antiretroviral properties of S/GSK1349572, a nextgeneration HIV integrase inhibitor. Antimicrob Agents Chemother 55:813-821. http://dx.doi.org/10.1128/AAC.01209-10.
19. Hazuda DJ, Young SD, Guare JP, Anthony NJ, Gomez RP, Wai JS, Vacca JP, Handt L, Motzel SL, Klein HJ, Dornadula G, Danovich RM, Witmer MV, Wilson KA, Tussey L, Schleif WA, Gabryelski LS, Jin L, Miller MD, Casimiro DR, Emini EA, Shiver JW. 2004. Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques. Science 305:528-532. http://dx.doi.org/10.1126/science.1098632.
20. Xu HT, Asahchop EL, Oliveira M, Quashie PK, Quan Y, Brenner BG, Wainberg MA. 2011. Compensation by the E138K mutation in HIV-1 reverse transcriptase for deficits in viral replication capacity and enzyme processivity associated with the M184I/V mutations. J Virol 85:11300-11308. http://dx.doi.org/10.1128/JVI.05584-11.
21. Wares M, Mesplède T, Quashie PK, Osman N, Han Y, Wainberg MA. 2014. The M50I polymorphic substitution in association with the R263K mutation in HIV-1 subtype B integrase increases drug resistance but does not restore viral replicative fitness. Retrovirology 11:7. http://dx.doi.org/10.1186/1742-4690-11-7.
22. Hassounah SA, Mesplède T, Quashie PK, Oliveira M, Sandstrom PA, Wainberg MA. 2014. Effect of HIV-1 integrase resistance mutations when introduced into SIVmac239 on susceptibility to integrase strand transfer inhibitors. J Virol 88:9683-9692. http://dx.doi.org/10.1128/JVI.00947-14.
23. Molina JM, Lamarca A, Andrade-Villanueva J, Clotet B, Clumeck N, Liu YP, Zhong L, Margot N, Cheng AK, Chuck SL. 2012. Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, noninferiority study. Lancet Infect Dis 12: 27-35. http://dx.doi.org/10.1016/S1473-3099(11)70249-3.
24. DeJesus E, Rockstroh JK, Henry K, Molina JM, Gathe J, Ramanathan S, Wei X, Yale K, Szwarcberg J, White K, Cheng AK, Kearney BP. 2012. Coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, noninferiority trial. Lancet 379: 2429-2438. http://dx.doi.org/10.1016/S0140-6736(12)60918-0.
25. Sax PE, DeJesus E, Mills A, Zolopa A, Cohen C, Wohl D, Gallant JE, Liu HC, Zhong L, Yale K, White K, Kearney BP, Szwarcberg J, Quirk E, Cheng AK. 2012. Coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus coformulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet 379:2439-2448. http://dx.doi.org/10.1016/S0140-6736(12)60917-9.
26. Rockstroh JK, DeJesus E, Henry K, Molina JM, Gathe J, Ramanathan S, Wei X, Plummer A, Abram M, Cheng AK, Fordyce MW, Szwarcberg J. 2013. A randomized, double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir DF versus ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 results. J Acquir Immune Defic Syndr 62:483-486. http://dx.doi.org/10.1097/QAI.0b013e318286415c.
27. Zolopa A, Sax PE, DeJesus E, Mills A, Cohen C, Wohl D, Gallant JE, Liu HC, Plummer A, White KL, Cheng AK, Rhee MS, Szwarcberg J. 2013. A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 results. J Acquir Immune Defic Syndr 63: 96-100. http://dx.doi.org/10.1097/QAI.0b013e318289545c.
28. Elion R, Molina JM, Ramon Arribas Lopez J, Cooper D, Maggiolo F, Wilkins E, Conway B, Liu YP, Margot N, Rhee M, Chuck SL, Szwarcberg J. 2013. A randomized phase 3 study comparing oncedaily elvitegravir with twice-daily raltegravir in treatment-experienced subjects with HIV-1 infection: 96-week results. J Acquir Immune Defic Syndr 63:494-497. http://dx.doi.org/10.1097/QAI.0b013e318298469c.
29. Quashie PK, Mesplède T, Han YS, Veres T, Osman N, Hassounah S, Sloan RD, Xu HT, Wainberg MA. 2013. Biochemical analysis of the role of G118R-linked dolutegravir drug resistance substitutions in HIV-1 integrase. Antimicrob Agents Chemother 57:6223-6235. http://dx.doi.org/10.1128/AAC.01835-13.
30. Mesplède T, Wainberg MA. 2014. Is resistance to dolutegravir possible when this drug is used in first-line therapy? Viruses 6:3377-3385. http://dx.doi.org/10.3390/v6093377.
31. Mesplède T, Quashie PK, Osman N, Han Y, Singhroy DN, Lie Y, Petropoulos CJ, Huang W, Wainberg MA. 2013. Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure. Retrovirology 10:22. http://dx.doi.org/10.1186/1742-4690-10-22.
32. Mesplède T, Osman N, Wares M, Quashie PK, Hassounah S, Anstett K, Han Y, Singhroy DN, Wainberg MA. 2014. Addition of E138K to R263K in HIV integrase increases resistance to dolutegravir, but fails to restore activity of the HIV integrase enzyme and viral replication capacity. J Antimicrob Chemother 69:2733-2740. http://dx.doi.org/10.1093/jac/dku199.
33. Marinello J, Marchand C, Mott BT, Bain A, Thomas CJ, Pommier Y. 2008. Comparison of raltegravir and elvitegravir on HIV-1 integrase catalytic reactions and on a series of drug-resistant integrase mutants. Biochemistry 47:9345-9354. http://dx.doi.org/10.1021/bi800791q.
34. Margot NA, Hluhanich RM, Jones GS, Andreatta KN, Tsiang M, McColl DJ, White KL, Miller MD. 2012. In vitro resistance selections using elvitegravir, raltegravir, and two metabolites of elvitegravir M1 and M4. Antiviral Res 93:288-296. http://dx.doi.org/10.1016/j.antiviral.2011.12.008.
35. Le Sage V, Mouland AJ, Valiente-Echeverria F. 2014. Roles of HIV-1 capsid in viral replication and immune evasion. Virus Res 193:116-129. http://dx.doi.org/10.1016/j.virusres.2014.07.010.
36. Wainberg MA, Zaharatos GJ, Brenner BG. 2011. Development of antiretroviral drug resistance. N Engl J Med 365:637-646. http://dx.doi.org/10.1056/NEJMra1004180.
37. Hu Z, Kuritzkes DR. 2011. Interaction of reverse transcriptase (RT) mutations conferring resistance to lamivudine and etravirine: effects on fitness and RT activity of human immunodeficiency virus type 1. J Virol 85:11309-11314. http://dx.doi.org/10.1128/JVI.05578-11.
38. Delelis O, Thierry S, Subra F, Simon F, Malet I, Alloui C, Sayon S, Calvez V, Deprez E, Marcelin AG, Tchertanov L, Mouscadet JF. 2010. Impact of Y143 HIV-1 integrase mutations on resistance to raltegravir in vitro and in vivo. Antimicrob Agents Chemother 54:491-501. http://dx.doi.org/10.1128/AAC.01075-09.
39. Mbisa JL, Martin SA, Cane PA. 2011. Patterns of resistance development with integrase inhibitors in HIV. Infect Drug Resist 4:65-76. http://dx.doi.org/10.2147/IDR.S7775.